Developer docs
API playgroundTry for free, no card

Search company profiles

Illinois CancerCare

Full company profile

uuid000l48q

Namestring
Illinois CancerCare
Legal namestring
Illinois CancerCare, P.C.
Company typeenum
Private
Founded yearint
1977
Descriptiontext

Illinois CancerCare, P.C. is a private professional corporation headquartered in Peoria, Illinois, operating as one of the largest community oncology and hematology practices in the United States. Founded in 1977 by Dr. Stephen Cullinan, the practice operates 14 clinic locations across Central and Western Illinois, staffed by 22 physicians, 39+ advanced practice providers, 100+ oncology-certified nurses, and more than 500 staff members. The practice serves patients diagnosed with cancer and blood disorders, including benign hematology, and extends services to survivors and individuals with family history of cancer through genetic counseling and testing.

The clinical offering is an integrated oncology stack delivered under one corporate structure: physician-led treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, palliative care), on-site laboratory services (CBC, chemistry, tumor markers, bone marrow biopsy), advanced diagnostic imaging (CT, FDG PET/CT, Pylarify PSMA PET/CT, Copper 64 Dotatate PET/CT, Cerianna PET/CT, X-Ray, DEXA), a URAC-accredited specialty pharmacy with sterile IV compounding and investigational drug services, genetic counseling and testing, oncology counseling, oncology nutrition, and a Cancer SurvivorCare program. The technology infrastructure is conventional healthcare IT — electronic health records, an electronic queue system for patient flow, automated medication management in IV Prep, and a patient portal — with no disclosed AI or machine learning components.

The business model is reimbursement-based, with revenue generated from patient care services billed to commercial insurance, Medicare, and Medicaid, plus prescription fills from the integrated pharmacy and per-enrollment/per-procedure compensation from clinical trial sponsors (NCORP, Sarah Cannon Research Institute, Pfizer, and other pharmaceutical partners). Patient acquisition is driven primarily by physician referrals through a dedicated referral portal, supplemented by self-referrals, second opinions, and community outreach (newsletters, volunteer programs, patient testimonials, and Facebook). Recent strategic moves — the 2024 US Oncology Network partnership (backed by McKesson), the 2025 Sarah Cannon Research Institute partnership, ongoing retail pharmacy expansion, and the first-in-world enrollment on a Pfizer Phase 3 lung cancer trial — signal an intent to scale the community oncology platform while preserving independent physician ownership.

Short descriptiontext

Illinois CancerCare is a private community oncology and hematology practice operating 14 clinic locations across Central and Western Illinois with 22 physicians, 39+ advanced practice providers, and 500+ staff, delivering integrated cancer treatment, imaging, lab, pharmacy, and clinical trial services to regional cancer and blood disorder patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPeoria, United States
HQ citystring
Peoria
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices13 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology treatment services, hematology care, cancer clinical trials, specialty pharmacy services, diagnostic imaging oncology
Industry2 codes
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAFAC
Radiation Oncology
NAICS code1 code
  • Offices of Physicians62111
SIC code1 code
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Oncology and Hematology Care Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Patient Care Services
TypeSubscription Recurring
Description

Revenue generated from comprehensive oncology and hematology treatment services including chemotherapy, targeted therapy, biological therapy, hormonal therapy, diagnostic imaging, laboratory services, and supportive care. Billed through insurance (commercial, Medicare, Medicaid) and patient self-pay.

illinoiscancercare.com
2Pharmacy Services
TypeTransaction Fee
Description

In-house specialty pharmacy providing outpatient prescription medications, clinical pharmacy services, and investigational drug services. Revenue from prescription fills billed to insurance and self-pay patients.

illinoiscancercare.com
3Clinical Trial Participation
TypeProfessional Services
Description

Revenue from conducting clinical trials in partnership with NCI Community Oncology Research Program (NCORP), Sarah Cannon Research Institute, and pharmaceutical companies. Includes compensation for patient enrollment, study procedures, and drug dispensing.

illinoiscancercare.com
4Genetic Testing and Counseling
TypeSubscription Recurring
Description

Genetic counseling and testing services for inherited cancer risk assessment. Revenue from insurance reimbursement and patient self-pay for counseling visits and laboratory testing.

illinoiscancercare.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1Insurance-based healthcare services with co-pay at time of service
ModelSubscriptionBilling cadencePer visit
Notes

Co-payment expected at time of service. The practice accepts checks, Visa, Mastercard, or Discover. No cash accepted. Responsibility for all bills remains with the patient after insurance processing. Payment plans available.

illinoiscancercare.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Illinois CancerCare is a private professional oncology and hematology practice delivering comprehensive cancer diagnosis and treatment including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiation oncology consultation. The practice provides integrated in-house specialty pharmacy, advanced diagnostic imaging (CT, FDG PET/CT, PSMA PET/CT, DEXA), on-site laboratory services, and an active clinical trials program with 80-120 active studies at any time. Supporting services include oncology counseling, nutrition programs, genetic testing and counseling, and Cancer SurvivorCare for post-treatment follow-up.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 14,000+ patients enrolled in clinical trials since 1978
+4 more records
Product overview1 text field

Illinois CancerCare is a comprehensive oncology and hematology practice offering a unified suite of cancer and blood disorder care services. The core clinical offerings include Cancer Treatment Services (chemotherapy, immunotherapy, targeted therapy, hormonal therapy), Blood Disorders Treatment, Genetics Clinics, and Pharmacy Services. These are supported by diagnostic services including on-site Laboratory Services and Diagnostic Imaging (CT, PET/CT, X-ray, DEXA). Patient support services encompass Oncology Counseling, Oncology Nutrition Programs, Cancer SurvivorCare, and Drug Therapy Education. The practice operates a robust Clinical Trials Program with partnerships with NCORP and Sarah Cannon Research Institute, offering 100+ active trials. Additional patient-facing services include a Patient Portal, Bill Pay, and a New Patient Video Library. With 14 clinic locations across central Illinois, the practice provides care through 22 physicians, 39+ Advanced Practice Providers, 100+ nurses, and 500+ total staff members.

Product and service11 records
1Cancer Treatment Services
CategoryClinical Oncology Care
Description

Comprehensive oncology treatment including chemotherapy, targeted therapy, biological therapy (immunotherapy), hormonal therapy, and palliative care, with personalized treatment plans based on individual cancer biology. For patients diagnosed with cancer across Central and Western Illinois.

2Blood Disorders Treatment
CategoryClinical Hematology Care
Description

Expert hematology care for benign and malignant blood disorders including anemia, platelet disorders, clotting disorders, leukemia, lymphoma, and myeloma, with a specialized Benign Hematology Clinic. For patients with abnormal blood counts or diagnosed blood disorders.

3Genetics Clinics
CategoryClinical Oncology Care
Description

Genetic testing and counseling to identify inherited cancer risks, guide personalized treatment decisions, and support family screening. Includes Lynch syndrome screening and breast cancer risk assessment. For individuals concerned about inherited cancer risk based on personal or family history.

4Pharmacy Services
CategorySpecialty Pharmacy
Description

Comprehensive in-house pharmacy comprising URAC-accredited retail specialty pharmacy, IV Prep (sterile compounding), clinical pharmacist services, and investigational drug services for clinical trials. Over 60 staff members support patient medication management across six retail pharmacy locations.

5Oncology Counseling Services
CategoryPatient Support Services
Description

Emotional support and guidance for cancer patients and families through individual counseling, support groups (Circle of Support, Gynecological Cancer Support Group), available in-person, virtually, or by phone.

6Oncology Nutrition Programs
CategoryPatient Support Services
Description

Registered Dietitian services providing personalized nutrition plans to support healing and manage treatment side effects. Available at no cost to patients and caregivers.

7Laboratory Services
CategoryDiagnostic Services
Description

On-site laboratory offering comprehensive testing including CBC, chemistry panels, tumor markers, specialized myeloma testing, bone marrow aspiration and biopsy, and therapeutic phlebotomy.

8Diagnostic Imaging
CategoryDiagnostic Services
Description

Advanced imaging services including CT scans, FDG PET/CT, Pylarify PSMA PET/CT, Copper 64 Dotatate PET/CT, Cerianna PET/CT, Xofigo treatment, X-ray, and DEXA bone density scans at multiple clinic locations.

9Clinical Trials Program
CategoryClinical Research
Description

Award-winning research program offering 100+ active clinical trials at any given time, with over 14,000 patients enrolled since 1978. Partnerships with NCI Community Oncology Research Program (NCORP) and Sarah Cannon Research Institute.

10Cancer SurvivorCare
CategoryPatient Support Services
Description

Post-treatment survivorship program providing ongoing monitoring, management of treatment-related side effects, and coordination with oncologists for long-term health and quality of life. For cancer survivors transitioning from active treatment.

11Patient Portal
CategoryPatient Digital Services
Description

Online portal allowing patients to view records, manage appointments, and message their care team securely.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Sarah Cannon Research Institute (SCRI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

In 2025, Illinois CancerCare deepened its research leadership through a partnership with Sarah Cannon Research Institute, one of the world's premier cancer research organizations. This collaboration opens expanded pathways for groundbreaking clinical trials and innovative treatment options, significantly broadening the research portfolio.

illinoiscancercare.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

In 2024, Illinois CancerCare partnered with the US Oncology Network (USON), supported by McKesson. This landmark partnership elevates the practice's ability to deliver advanced therapies, expand clinical resources, and remain at the forefront of quality community-based cancer care. USON provides access to national resources, research networks, and operational expertise.

3Heartland Cancer Research NCORP
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Illinois CancerCare became a founding member of the Heartland Cancer Research NCI Community Oncology Research Program (Heartland NCORP) in 2014, receiving one of only 37 national NCORP grants. Renewed federal funding through 2025. Illinois CancerCare serves as a core member with Dr. Jane Liu as local principal investigator. The program brings NCI-supported cancer prevention, control, and treatment trials directly to local communities.

illinoiscancercare.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on1994-01-01
Description

Phase II cancer treatment research affiliation established in 1994, expanding access to innovative clinical trials for local patients through collaboration with the University of Chicago's research program.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on1983-01-01
Description

Partnership established in 1983 when Oncology Hematology Associates partnered with Methodist Medical Center to become one of the nation's first Community Clinical Oncology Programs (CCOP), accelerating access to NCI-supported cancer prevention, control, and treatment trials.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership to improve identification and support of individuals at increased risk for breast and ovarian cancer. Patients are screened for risk level, those identified as moderate or high risk are referred to the genetics team for education, risk management strategies, and personalized care plans.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Historical research partnership established 1978-1979 through the North Central Cancer Treatment Group (NCCTG). Dr. Stephen Cullinan helped establish this groundbreaking partnership. The Illinois Oncology Research Association (IORA) emerged as one of the original NCCTG member institutions.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with OSF Healthcare system including OSF Holy Family Medical Center in Monmouth, OSF Saint Francis Medical Center for dietetic internship, and OSF outreach radiation center at Peoria Cancer Center.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1The US Oncology Network
TypeDirect peer
Description

National network of community oncology practices; ILCC joined as a flagship affiliate in 2024. Direct peer in community-based oncology delivery, trial enrollment, and value-based care contracting across multiple U.S. regions.

TypeDirect peer
Description

One of the largest independent community oncology practices in the U.S., with comparable scale (multi-site clinics, in-house pharmacy, imaging, clinical trials, genetics). Closely comparable in operating model, talent composition, and value-based care orientation.

TypeDirect peer
Description

Large USON-affiliated community oncology practice with 200+ sites, in-house specialty pharmacy, imaging, and clinical research. Direct comparable in service breadth, geographic distribution, and trial portfolio.

TypeDirect peer
Description

Large independent community oncology and hematology practice with ~100 sites, in-house specialty pharmacy, central labs, and a top-tier clinical research program. Highly comparable operating model and research scale.

TypeDirect peer
Description

Multi-site community oncology and hematology practice offering medical oncology, infusion, imaging, lab, and clinical trials in the Upper Midwest. Comparable mid-size independent practice with research emphasis.

6Regional Cancer Care Associates
TypeDirect peer
Description

Multi-state community oncology practice network with on-site lab, imaging, and clinical trials. Comparable physician-led, multi-site oncology delivery model focused on community access.

TypeDirect peer
Description

Independent community oncology practice in the Cincinnati region offering medical oncology, hematology, infusion, imaging, lab, and clinical research. Comparable mid-size private practice operating model.

8Sarah Cannon Research Institute
TypeBroad incumbent
Description

One of the largest oncology research organizations in the world; partnered with ILCC in 2025. Broad incumbent in clinical trial management and early-phase oncology research — comparable research depth and pharma-sponsor relationships but at national scale.

TypeBroad incumbent
Description

National cancer research and treatment system (formerly including Cancer Treatment Centers of America). Comparable in offering comprehensive oncology, hematology, infusion, imaging, lab, and clinical trials, but at academic/NCI-comprehensive scale vs. ILCC's community setting.

10McKesson / US Oncology Research
TypeOthers
Description

Parent organization of the US Oncology Network; ILCC joined as a USON affiliate in 2024. Adjacent enabler providing drug distribution, oncology practice infrastructure, and research support — not a direct operator but a critical ecosystem participant.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Illinois CancerCare

Oncology and Hematology Care Servicesillinoiscancercare.com

Illinois CancerCare is a private community oncology and hematology practice operating 14 clinic locations across Central and Western Illinois with 22 physicians, 39+ advanced practice providers, and 500+ staff, delivering integrated cancer treatment, imaging, lab, pharmacy, and clinical trial services to regional cancer and blood disorder patients.

What Illinois CancerCare does

Illinois CancerCare, P.C. is a private professional corporation headquartered in Peoria, Illinois, operating as one of the largest community oncology and hematology practices in the United States. Founded in 1977 by Dr. Stephen Cullinan, the practice operates 14 clinic locations across Central and Western Illinois, staffed by 22 physicians, 39+ advanced practice providers, 100+ oncology-certified nurses, and more than 500 staff members. The practice serves patients diagnosed with cancer and blood disorders, including benign hematology, and extends services to survivors and individuals with family history of cancer through genetic counseling and testing.

The clinical offering is an integrated oncology stack delivered under one corporate structure: physician-led treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, palliative care), on-site laboratory services (CBC, chemistry, tumor markers, bone marrow biopsy), advanced diagnostic imaging (CT, FDG PET/CT, Pylarify PSMA PET/CT, Copper 64 Dotatate PET/CT, Cerianna PET/CT, X-Ray, DEXA), a URAC-accredited specialty pharmacy with sterile IV compounding and investigational drug services, genetic counseling and testing, oncology counseling, oncology nutrition, and a Cancer SurvivorCare program. The technology infrastructure is conventional healthcare IT — electronic health records, an electronic queue system for patient flow, automated medication management in IV Prep, and a patient portal — with no disclosed AI or machine learning components.

The business model is reimbursement-based, with revenue generated from patient care services billed to commercial insurance, Medicare, and Medicaid, plus prescription fills from the integrated pharmacy and per-enrollment/per-procedure compensation from clinical trial sponsors (NCORP, Sarah Cannon Research Institute, Pfizer, and other pharmaceutical partners). Patient acquisition is driven primarily by physician referrals through a dedicated referral portal, supplemented by self-referrals, second opinions, and community outreach (newsletters, volunteer programs, patient testimonials, and Facebook). Recent strategic moves — the 2024 US Oncology Network partnership (backed by McKesson), the 2025 Sarah Cannon Research Institute partnership, ongoing retail pharmacy expansion, and the first-in-world enrollment on a Pfizer Phase 3 lung cancer trial — signal an intent to scale the community oncology platform while preserving independent physician ownership.

Illinois CancerCare firmographics

Firmographics
Name
Illinois CancerCare
Legal name
Illinois CancerCare, P.C.
Website
https://illinoiscancercare.com
Company type
Private
Founded year
1977
Operating status
Operating
Headcount range
251–500 employees
Short description
Illinois CancerCare is a private community oncology and hematology practice operating 14 clinic locations across Central and Western Illinois with 22 physicians, 39+ advanced practice providers, and 500+ staff, delivering integrated cancer treatment, imaging, lab, pharmacy, and clinical trial services to regional cancer and blood disorder patients.
Ownership category
akta.pro rank

Illinois CancerCare industry classification

Industry
Product category
Oncology and Hematology Care Services
NAICS
Offices of Physicians (62111)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAFAC
Radiation Oncology

Keywords

  • Oncology treatment services
  • Hematology care
  • Cancer clinical trials
  • Specialty pharmacy services
  • Diagnostic imaging oncology

Where Illinois CancerCare is headquartered

Location

Headquarters

HQ city
Peoria
HQ country
United States
HQ region
North America

Offices13 records

Markets served

Illinois CancerCare business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Patient Care Services: Revenue generated from comprehensive oncology and hematology treatment services including chemotherapy, targeted therapy, biological therapy, hormonal therapy, diagnostic imaging, laboratory services, and supportive care. Billed through insurance (commercial, Medicare, Medicaid) and patient self-pay.
  2. Pharmacy Services: In-house specialty pharmacy providing outpatient prescription medications, clinical pharmacy services, and investigational drug services. Revenue from prescription fills billed to insurance and self-pay patients.
  3. Clinical Trial Participation: Revenue from conducting clinical trials in partnership with NCI Community Oncology Research Program (NCORP), Sarah Cannon Research Institute, and pharmaceutical companies. Includes compensation for patient enrollment, study procedures, and drug dispensing.
  4. Genetic Testing and Counseling: Genetic counseling and testing services for inherited cancer risk assessment. Revenue from insurance reimbursement and patient self-pay for counseling visits and laboratory testing.

Pricing tiers

ModelBillingPrice
SubscriptionPer visitInsurance-based healthcare services with co-pay at time of service

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Illinois CancerCare product offering

Product offering

Core offering

Illinois CancerCare is a private professional oncology and hematology practice delivering comprehensive cancer diagnosis and treatment including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiation oncology consultation. The practice provides integrated in-house specialty pharmacy, advanced diagnostic imaging (CT, FDG PET/CT, PSMA PET/CT, DEXA), on-site laboratory services, and an active clinical trials program with 80-120 active studies at any time. Supporting services include oncology counseling, nutrition programs, genetic testing and counseling, and Cancer SurvivorCare for post-treatment follow-up.

Product overview

Illinois CancerCare is a comprehensive oncology and hematology practice offering a unified suite of cancer and blood disorder care services. The core clinical offerings include Cancer Treatment Services (chemotherapy, immunotherapy, targeted therapy, hormonal therapy), Blood Disorders Treatment, Genetics Clinics, and Pharmacy Services. These are supported by diagnostic services including on-site Laboratory Services and Diagnostic Imaging (CT, PET/CT, X-ray, DEXA). Patient support services encompass Oncology Counseling, Oncology Nutrition Programs, Cancer SurvivorCare, and Drug Therapy Education. The practice operates a robust Clinical Trials Program with partnerships with NCORP and Sarah Cannon Research Institute, offering 100+ active trials. Additional patient-facing services include a Patient Portal, Bill Pay, and a New Patient Video Library. With 14 clinic locations across central Illinois, the practice provides care through 22 physicians, 39+ Advanced Practice Providers, 100+ nurses, and 500+ total staff members.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cancer Treatment Services Comprehensive oncology treatment including chemotherapy, targeted therapy, biological therapy (immunotherapy), hormonal therapy, and palliative care, with personalized treatment plans based on individual cancer biology. For patients diagnosed with cancer across Central and Western Illinois.
  • Blood Disorders Treatment Expert hematology care for benign and malignant blood disorders including anemia, platelet disorders, clotting disorders, leukemia, lymphoma, and myeloma, with a specialized Benign Hematology Clinic. For patients with abnormal blood counts or diagnosed blood disorders.
  • Genetics Clinics Genetic testing and counseling to identify inherited cancer risks, guide personalized treatment decisions, and support family screening. Includes Lynch syndrome screening and breast cancer risk assessment. For individuals concerned about inherited cancer risk based on personal or family history.
  • Pharmacy Services Comprehensive in-house pharmacy comprising URAC-accredited retail specialty pharmacy, IV Prep (sterile compounding), clinical pharmacist services, and investigational drug services for clinical trials. Over 60 staff members support patient medication management across six retail pharmacy locations.
  • Oncology Counseling Services Emotional support and guidance for cancer patients and families through individual counseling, support groups (Circle of Support, Gynecological Cancer Support Group), available in-person, virtually, or by phone.
  • Oncology Nutrition Programs Registered Dietitian services providing personalized nutrition plans to support healing and manage treatment side effects. Available at no cost to patients and caregivers.
  • Laboratory Services On-site laboratory offering comprehensive testing including CBC, chemistry panels, tumor markers, specialized myeloma testing, bone marrow aspiration and biopsy, and therapeutic phlebotomy.
  • Diagnostic Imaging Advanced imaging services including CT scans, FDG PET/CT, Pylarify PSMA PET/CT, Copper 64 Dotatate PET/CT, Cerianna PET/CT, Xofigo treatment, X-ray, and DEXA bone density scans at multiple clinic locations.
  • Clinical Trials Program Award-winning research program offering 100+ active clinical trials at any given time, with over 14,000 patients enrolled since 1978. Partnerships with NCI Community Oncology Research Program (NCORP) and Sarah Cannon Research Institute.
  • Cancer SurvivorCare Post-treatment survivorship program providing ongoing monitoring, management of treatment-related side effects, and coordination with oncologists for long-term health and quality of life. For cancer survivors transitioning from active treatment.
  • Patient Portal Online portal allowing patients to view records, manage appointments, and message their care team securely.

Quantifiable outcome

  • 14,000+ patients enrolled in clinical trials since 1978
  • +4 more outcomes

Companies that use Illinois CancerCare

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Illinois CancerCare technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Illinois CancerCare partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, flagship and supporting.

  • Sarah Cannon Research Institute (SCRI)coreStrategic or Co-development Partner · 1 January 2025In 2025, Illinois CancerCare deepened its research leadership through a partnership with Sarah Cannon Research Institute, one of the world's premier cancer research organizations. This collaboration opens expanded pathways for groundbreaking clinical trials and innovative treatment options, significantly broadening the research portfolio.
  • US Oncology Network (USON)flagshipStrategic or Co-development Partner · 1 January 2024In 2024, Illinois CancerCare partnered with the US Oncology Network (USON), supported by McKesson. This landmark partnership elevates the practice's ability to deliver advanced therapies, expand clinical resources, and remain at the forefront of quality community-based cancer care. USON provides access to national resources, research networks, and operational expertise.
  • Heartland Cancer Research NCORPcoreStrategic or Co-development Partner · 1 January 2014Illinois CancerCare became a founding member of the Heartland Cancer Research NCI Community Oncology Research Program (Heartland NCORP) in 2014, receiving one of only 37 national NCORP grants. Renewed federal funding through 2025. Illinois CancerCare serves as a core member with Dr. Jane Liu as local principal investigator. The program brings NCI-supported cancer prevention, control, and treatment trials directly to local communities.
  • University of ChicagosupportingStrategic or Co-development Partner · 1 January 1994Phase II cancer treatment research affiliation established in 1994, expanding access to innovative clinical trials for local patients through collaboration with the University of Chicago's research program.
  • Methodist Medical CentersupportingStrategic or Co-development Partner · 1 January 1983Partnership established in 1983 when Oncology Hematology Associates partnered with Methodist Medical Center to become one of the nation's first Community Clinical Oncology Programs (CCOP), accelerating access to NCI-supported cancer prevention, control, and treatment trials.
  • Susan G. Komen Breast CentersupportingStrategic or Co-development PartnerPartnership to improve identification and support of individuals at increased risk for breast and ovarian cancer. Patients are screened for risk level, those identified as moderate or high risk are referred to the genetics team for education, risk management strategies, and personalized care plans.
  • Mayo ClinicsupportingStrategic or Co-development PartnerHistorical research partnership established 1978-1979 through the North Central Cancer Treatment Group (NCCTG). Dr. Stephen Cullinan helped establish this groundbreaking partnership. The Illinois Oncology Research Association (IORA) emerged as one of the original NCCTG member institutions.
  • OSF HealthcaresupportingChannel Partner/ Reseller/ DistributorPartnership with OSF Healthcare system including OSF Holy Family Medical Center in Monmouth, OSF Saint Francis Medical Center for dietetic internship, and OSF outreach radiation center at Peoria Cancer Center.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Illinois CancerCare competitors and assessment

Company assessment

Direct peers

  • The US Oncology Network: National network of community oncology practices; ILCC joined as a flagship affiliate in 2024. Direct peer in community-based oncology delivery, trial enrollment, and value-based care contracting across multiple U.S. regions.
  • Tennessee Oncology: One of the largest independent community oncology practices in the U.S., with comparable scale (multi-site clinics, in-house pharmacy, imaging, clinical trials, genetics). Closely comparable in operating model, talent composition, and value-based care orientation.
  • Texas Oncology: Large USON-affiliated community oncology practice with 200+ sites, in-house specialty pharmacy, imaging, and clinical research. Direct comparable in service breadth, geographic distribution, and trial portfolio.
  • Florida Cancer Specialists & Research Institute: Large independent community oncology and hematology practice with ~100 sites, in-house specialty pharmacy, central labs, and a top-tier clinical research program. Highly comparable operating model and research scale.
  • Minnesota Oncology: Multi-site community oncology and hematology practice offering medical oncology, infusion, imaging, lab, and clinical trials in the Upper Midwest. Comparable mid-size independent practice with research emphasis.
  • Regional Cancer Care Associates: Multi-state community oncology practice network with on-site lab, imaging, and clinical trials. Comparable physician-led, multi-site oncology delivery model focused on community access.
  • Oncology Hematology Care (OHC): Independent community oncology practice in the Cincinnati region offering medical oncology, hematology, infusion, imaging, lab, and clinical research. Comparable mid-size private practice operating model.

Broad incumbents

  • Sarah Cannon Research Institute: One of the largest oncology research organizations in the world; partnered with ILCC in 2025. Broad incumbent in clinical trial management and early-phase oncology research — comparable research depth and pharma-sponsor relationships but at national scale.
  • City of Hope: National cancer research and treatment system (formerly including Cancer Treatment Centers of America). Comparable in offering comprehensive oncology, hematology, infusion, imaging, lab, and clinical trials, but at academic/NCI-comprehensive scale vs. ILCC's community setting.

Others

  • McKesson / US Oncology Research: Parent organization of the US Oncology Network; ILCC joined as a USON affiliate in 2024. Adjacent enabler providing drug distribution, oncology practice infrastructure, and research support — not a direct operator but a critical ecosystem participant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Illinois CancerCare social profiles

Digital presence

Illinois CancerCare compliance and trust

Trust signal

Compliance3 records

Illinois CancerCare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Illinois CancerCare leadership team

Management profile

Number of profiles

Profiles3 records

Illinois CancerCare subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Illinois CancerCare funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Illinois CancerCare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Illinois CancerCare

What does Illinois CancerCare do?

Illinois CancerCare is a private professional oncology and hematology practice delivering comprehensive cancer diagnosis and treatment including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiation oncology consultation. The practice provides integrated in-house specialty pharmacy, advanced diagnostic imaging (CT, FDG PET/CT, PSMA PET/CT, DEXA), on-site laboratory services, and an active clinical trials program with 80-120 active studies at any time. Supporting services include oncology counseling, nutrition programs, genetic testing and counseling, and Cancer SurvivorCare for post-treatment follow-up.

Is Illinois CancerCare a public or private company?

Illinois CancerCare is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Illinois CancerCare founded?

Illinois CancerCare was founded in 1977. It employs 251 to 500 people.

Where is Illinois CancerCare based?

Illinois CancerCare is headquartered in Peoria, United States, in the North America region.

How does Illinois CancerCare make money?

Four revenue lines are on record. Patient Care Services are the primary driver. The others are pharmacy Services, clinical Trial Participation and genetic Testing and Counseling.

Who are Illinois CancerCare's main competitors?

Direct peers on record are The US Oncology Network, Tennessee Oncology, Texas Oncology, Florida Cancer Specialists & Research Institute, Minnesota Oncology, Regional Cancer Care Associates and Oncology Hematology Care (OHC). Broad incumbents are Sarah Cannon Research Institute and City of Hope. McKesson / US Oncology Research is listed as an others.

Does Illinois CancerCare have an API?

No public API is recorded for Illinois CancerCare.

What industry is Illinois CancerCare in?

Illinois CancerCare's product category is Oncology and Hematology Care Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 62111 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals